Kyverna Therapeutics Inc. Common Stock (KYTX)

About KYTX

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole bl…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

149

Website

kyvernatx.com/

Fundamentals

1-day range

$8.31$8.54

Market cap

$471.16M

P/E (trailing)

—

P/E (forward)

-2.73

EPS (trailing)

$-3.28

Dividend yield

—

Beta

2.03

Avg. volume

991.0K

Forecasts

5 analyst ratings

Kyverna Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KYTX

  Kyverna Therapeutics Inc. Common Stock

  $8.36

  ▼ 3.24%
  Market cap $471.16MP/E —
  $3.55$13.67
• VALN

  Valneva SE American Depositary Shares

  $6.43

  ▼ 2.13%
  Market cap $491.51MP/E —
  $2.03$5.34
• CABA

  Cabaletta Bio Inc. Common Stock

  $3.11

  ▼ 7.99%
  Market cap $450.03MP/E —
  $1.4$4.23
• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $495.38MP/E —
  $1.3$3.48
• OCGN

  Ocugen Inc. Common Stock

  $1.32

  ▼ 3.65%
  Market cap $420.50MP/E —
  $1$2.73
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $528.15MP/E —
  $5.37$17.58
• SCTX

  Scribe Therapeutics Inc. Common Stock

  $28.44

  ▼ 1.39%
  Market cap $411.18MP/E —

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Adicet Bio: A Cheap Gamma Delta T-Cell Play
  SeekingAlpha · 8/14/2026
• Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval
  SeekingAlpha · 8/13/2026
• Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
  Yahoo · 8/11/2026
• Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
  Benzinga · 8/11/2026

• Mert Aktar · May 27, 2026 · Grant

  20.6K
• Mert Aktar · May 27, 2026 · Grant

  5.1K
• Christi Shaw · May 27, 2026 · Tax Withholding

  4.2K @ $8.59
• Fred E. Cohen · May 27, 2026 · Grant

  20.6K
• Fred E. Cohen · May 27, 2026 · Grant

  5.1K
• Ian T. Clark · May 27, 2026 · Grant

  20.6K
• Ian T. Clark · May 27, 2026 · Grant

  5.1K
• Beth C. Seidenberg · May 27, 2026 · Grant

  20.6K
• Beth C. Seidenberg · May 27, 2026 · Grant

  5.1K
• Dac Nadia · May 4, 2026 · Grant

  300.0K
• Naji Gehchan · March 13, 2026 · Grant

  105.0K
• Naji Gehchan · March 13, 2026 · Grant

  18.0K
• Warner Weston Biddle · March 13, 2026 · Grant

  350.0K
• Warner Weston Biddle · March 13, 2026 · Grant

  58.0K
• Marc Grasso · March 13, 2026 · Grant

  65.0K

Institutional Ownership

March 31, 2026

Total shares held

34.69M

Total value held

$285.87M

Institutional holders

108